RELEASE: Minaris Regenerative Medicine Selects Veeva Vault Quality Suite Applications

-Minaris Regenerative Medicine streamlines contract manufacturing with Veeva Vault Quality Suite applications

Global CDMO unifies quality content and training for greater visibility and agility

BARCELONA, Spain, May 24, 2023/PRNewswire/ -- Veeva Systems (NYSE: VEEV) announced today that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, has selected Veeva Vault QualityDocs and Veeva Vault Training to advance your global quality operations. Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance.

"As pioneers in cell and gene therapy, we needed a scalable quality management foundation to drive efficiency and compliance," said Prakash Manwani, Chief Digital Officer, Minaris Regenerative Medicine. "With Veeva Vault Quality Suite applications, we are well positioned for GxP document control and continuous quality improvement. Veeva as a platform is a critical piece of our overall IT vision and roadmap to create a digitally connected ecosystem for our operations. , clients and patients alike".

Minaris Regenerative Medicine's vision is to "create future cell therapy miracles together," and the Veeva platform will enhance its ability to do so, benefiting both its clients and patients suffering from a wide range of diseases for which the therapy cellular and genetic is a promise. CDMO will use Veeva Vault Quality Suite applications to modernize its operations globally, including Vault QualityDocs to control access and distribution of content and Vault Training to create and manage role-based learning programs. By adopting connected applications on a single platform, Minaris Regenerative Medicine will streamline its global quality processes.

"Veeva gives us easy access to documentation and training for greater on-site agility," said Adela Balducci, executive director, chief quality officer, North America, Minaris Regenerative Medicine. "Being on the same Platform as many of our clients will provide efficiencies in information sharing and reporting, improving the way we work with clients for a competitive advantage."

"Minaris Regenerative Medicine is developing and manufacturing potentially life-changing cellular therapies to treat cancers and genetic disorders with no known cure," said Ashley McMillan, senior director of strategy for Veeva Vault Quality. "Veeva Vault Quality applications will be key to supporting the quality of these important therapies. We are excited to be a strategic partner in helping them transform content and employee qualification management."

Additional InformationFor more information about Veeva Vault Quality Suite, visit: veeva.com/Quality Manufacturing Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Minaris Regenerative Medicine Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our customers high value clinical and commercial manufacturing services, development solutions and technologies. We are pioneers in the field with over 20 years of experience providing outstanding quality and reliability. Our facilities in North America, Europe and Asia allow us to deliver life-changing therapies to patients around the world. Minaris Regenerative Medicine is part of the Resonac Group.

For more information, visit www.rm.minaris.com.

About Veeva Systems Veeva is the world leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world's largest biopharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit the website veeva.com/eu.

Veeva's Forward-Looking Statements This release contains forward-looking statements about Veeva's products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we are under no obligation to update such statements. There are numerous risks that have the potential to adversely affect our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find here (a summary of the risks that may impact our business can be found on pages 9 and 10), and in our subsequent filings with the SEC, which you can access at sec.gov.

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/minaris-regenerative-medicine-selecciona-las-aplicaciones-veeva-vault-quality-suite-301833758.html